Dynamic Advisor Solutions LLC Purchases 11,437 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Dynamic Advisor Solutions LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 60.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,491 shares of the biopharmaceutical company's stock after buying an additional 11,437 shares during the quarter. Dynamic Advisor Solutions LLC's holdings in Bristol Myers Squibb were worth $1,860,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Pinney & Scofield Inc. bought a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $28,000. Transce3nd LLC bought a new position in Bristol Myers Squibb during the fourth quarter worth $28,000. Finally, Global Wealth Strategies & Associates lifted its holdings in Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.09% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on BMY shares. Piper Sandler began coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. UBS Group lowered their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Finally, William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol Myers Squibb Stock Up 0.2%

Bristol Myers Squibb stock traded up $0.08 during trading on Friday, hitting $46.92. 9,727,497 shares of the company were exchanged, compared to its average volume of 13,230,425. The company has a market capitalization of $95.49 billion, a P/E ratio of 17.57, a PEG ratio of 1.39 and a beta of 0.38. The business's 50 day moving average is $48.28 and its 200 day moving average is $54.43. Bristol Myers Squibb Company has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the prior year, the business posted ($4.40) EPS. The business's revenue was down 5.6% compared to the same quarter last year. Analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.